Figure 2. In vivo 1 H MRS–detectable... | American Society of Hematology

Figure 2.

In vivo 1H MRS–detectable biomarkers of GLS inhibition vs tumor volume in MCL xenografts. The spectral peak areas of lactate (upper rows) and alanine (middle rows), normalized to the water signal, were measured by 1H MRS with an Hadamard Selective Multiquantum Coherence (HDMD-Sel-MQC) transfer pulse sequence. (A) A representative subcutaneous MCL xenograft and 1H MRS spectrum acquired with HDMD-Sel-MQC transfer pulse sequence on a 9.4T horizontal bore Bruker console. (B) MCL-SL tumor (n = 5 mice per control and CB-839–treated cohort). (C) JeKo-1 tumor (n = 5). (D) REC-1 tumor (n = 5). CB-839 was administered orally at 200 mg/kg, twice daily, with vehicle-treated controls included for each MCL tumor type.

In vivo ¹H MRS–detectable biomarkers of GLS inhibition vs tumor volume in MCL xenografts. The spectral peak areas of lactate (upper rows) and alanine (middle rows), normalized to the water signal, were measured by ¹H MRS with an Hadamard Selective Multiquantum Coherence (HDMD-Sel-MQC) transfer pulse sequence. (A) A representative subcutaneous MCL xenograft and ¹H MRS spectrum acquired with HDMD-Sel-MQC transfer pulse sequence on a 9.4T horizontal bore Bruker console. (B) MCL-SL tumor (n = 5 mice per control and CB-839–treated cohort). (C) JeKo-1 tumor (n = 5). (D) REC-1 tumor (n = 5). CB-839 was administered orally at 200 mg/kg, twice daily, with vehicle-treated controls included for each MCL tumor type.

This Feature Is Available To Subscribers Only